In this week's diary I reflect on the impact of trauma in our lives following an unexpected medical emergency at home. This has fuelled my passion for what we are doing here at Psyence and the positive impact we could have on the lives of so many people.
Today Dr. Neil Maresky joins Psyence as Chief Executive Officer. Dr. Maresky brings more than 20 years of biopharmaceutical expertise to our team; he will oversee strategy and operations of Psyence, and will be based in Canada. Dr. Maresky has been instrumental in the launch, commercialization, and uptake of many ground breaking innovations, which have positively impacted the health of millions of patients across Canada.
This protected indigenous forest is the jewel of South Africa’s Garden Route, second only in popularity among foreign tourists to the Kruger National Park. It is also home to an incredible array of mushroom species.
On 20 June 2021 we celebrate the inaugural World Psychedelic Day. This day has been set aside to recognise a new era of rational and informed perspectives on modern day psychedelics and traditional psychoactive plant medicines. To mark this day, we asked some of our team why they believe in the healing power of psychedelics and natural plant-based medicine.
Collaboration with the Scientific Research Council (SRC) of Jamaica for Psilocybin Product Development
Psyence Group Announces a Collaboration with the Scientific Research Council (SRC) of Jamaica for Psilocybin Product Development
I am a strong believer that in business, one always has to mitigate risk. Yes, we are focusing on psilocybin and doing some incredibly exciting work in this space, but parallel to this we are also building a business in mental health and mental wellness.
In this episode I share the story of Psyence and how it came into being. From receiving a full license to cultivate, process, import, produce and export Psilocybin mushrooms just over a year ago, to designing and building out our commercial facility, a lot has been achieved in a short time.
Psyence establishes Psyence Jamaica as part of its strategy to develop standardized nutraceutical and pharmaceutical psychedelic products in Jamaica for the treatment of psychological traumas.
It’s been an exciting four months since we listed Psyence on the CSE January 2021. My team and I have been hard at work since then, perfecting our strategy, commencing operations, product development and making sure that we are hyper focused on what we are trying to achieve.